Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24916768 | 0.82 | — | — | |
| SCHEMBL16351522 | 0.78 | TSHR (0.31) | TSHRSMN1; SMN2POLBMAPTTDP1 | |
| SCHEMBL1930323 | 0.77 | ALDH1A1 (0.37) | TSHRSMN1; SMN2POLBMAPTTDP1 | |
| SCHEMBL15588784 | 0.76 | TSHR (0.31) | TSHRSMN1; SMN2POLBMAPTTDP1 | |
| SCHEMBL24916693 | 0.75 | — | — | |
| SCHEMBL20127258 | 0.73 | TSHR (0.33) | TSHRSMN1; SMN2POLBMAPTTDP1 | |
| SCHEMBL25956457 | 0.71 | TSHR (0.33) | TSHRSMN1; SMN2POLBMAPTTDP1 | |
| SCHEMBL9425117 | 0.69 | TSHR (0.46) | TSHRSMN1; SMN2POLBMAPTTDP1 | |
| SCHEMBL15737121 | 0.69 | TSHR (0.32) | TSHRSMN1; SMN2POLBMAPTTDP1 | |
| SCHEMBL12232722 | 0.69 | NQO1 (0.36) | TSHRSMN1; SMN2POLBMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192960-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230293701-A1 | LIGAND COMPOUNDS, CONJUGATES, AND APPLICATIONS THEREOF | ARGORNA PHARMACEUTICALS CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| EP-4227342-A1 | ESTER COMPOUND AND RESIN COMPOSITION | AJINOMOTO CO., INC. (JP) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023073243-A1 | INJECTABLE TOUGH AND VISCOELASTIC BTA HYDROGEL | UNIVERSITEIT MAASTRICHT (NL) | 2023-05-04 | — | — | WO | disclosed |
| US-11312964-B2 | Compositions and methods for modulating growth hormone receptor expression | IONIS PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| WO-2022075383-A1 | ESTER COMPOUND AND RESIN COMPOSITION | 味の素株式会社 | 2022-04-14 | — | — | WO | disclosed |
| US-20210207146-A1 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2021-07-08 | — | — | US | disclosed |
| US-20210087566-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | IONIS PHARMACEUTICALS, INC. | 2021-03-25 | — | — | US | disclosed |
| US-10844379-B2 | Conjugated antisense compounds and their use | IONIS PHARMACEUTICALS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| EP-2992009-B1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (A) EXPRESSION | IONIS PHARMACEUTICALS INC (US) | 2020-06-24 | — | — | EP | disclosed |
| US-9994855-B2 | Compositions and methods for modulating growth hormone receptor expression | IONIS PHARMACEUTICALS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9957292-B2 | Compositions and methods for modulating angiopoietin-like 3 expression | IONIS PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170166899-A1 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-15 | — | — | US | disclosed |
| WO-2015116867-A1 | QUINONE-MASKED PROBES AS LABELING REAGENTS FOR CELL UPTAKE MEASUREMENTS | PROMEGA CORPORATION (US) | 2015-08-06 | — | — | WO | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | TSHR 162/4885SMN1; SMN2 3787/4885POLB 757/4885 |
| US-20210087566-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | APOB, APOL1, LDLR | TSHR 3688/4885SMN1; SMN2 3310/4885POLB 3193/4885 |
| US-20230293701-A1 | LIGAND COMPOUNDS, CONJUGATES, AND APPLICATIONS THEREOF | ASGR1, HAVCR2, SLC10A1 | TSHR 385/4885SMN1; SMN2 3779/4885POLB 3376/4885 |
| US-10844379-B2 | Conjugated antisense compounds and their use | CSGALNACT1, GALNT1, GALNT6 | TSHR 2436/4885SMN1; SMN2 266/4885POLB 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.